Supreme Court Won’t Review FDA’s Fast-Track Approval Denial for Stomach Drug
- November 21, 2025
The U.S. Supreme Court declined November 17 to review a decision upholding the Food and Drug Administration’s (FDA’s) refusal to approve Vanda Pharmaceuticals, Inc.’s application for fast-track approval of its investigational new drug product tradipitant for treating a chronic stomach condition.
ARTICLE TAGS
You must be logged in to access this content.